What kind of vaccine is Vidprevtyn?
Vidprevtyn is a vaccine candidate against the coronavirus. It was developed in a collaboration between the French manufacturer Sanofi Pasteur and the British company GlaxoSmithKline (GSK). Vidprevtyn could round out the portfolio of available vaccine options for protection against the coronavirus in the foreseeable future.
Vidprevtyn belongs to the protein vaccines and thus formally to the dead vaccines. This mode of action is considered proven, reliable and has been used successfully in practice for many years – for example in vaccinations against hepatitis B, meningococcus B, HPV or for protection against seasonal influenza.
The main component of the vaccine is (recombinant) protein fragments of the spike protein, which correspond to those of the wild-type coronavirus. Manufacturers combine the artificially produced coronavirus protein fragments with an effect enhancer (adjuvant AS03).
Thus, unlike mRNA or vector vaccines, neither genetic information nor viral genetic material is temporarily introduced into the human cell to trigger a desired immune response against Sars-CoV-2.
